• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    1/2/24 7:15:59 AM ET
    $CLXT
    Agricultural Chemicals
    Industrials
    Get the next $CLXT alert in real time by email
    8-K
    false 0001705843 0001705843 2024-01-02 2024-01-02

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): January 2, 2024

     

     

    Cibus, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38161   27-1967997

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    6455 Nancy Ridge Drive

    San Diego, CA

      92121
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (858) 450-0008

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    symbol(s)

     

    Name of each exchange

    on which registered

    Class A Common Stock, $0.0001 par value per share   CBUS   The NASDAQ Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     


    Item 1.01

    Entry into a Material Definitive Agreement

    On January 2, 2024, Cibus, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated (“Stifel”). Pursuant to the terms of the Sales Agreement, the Company may offer and sell through Stifel, from time to time and at its sole discretion, shares of the Company’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”), having an aggregate offering price of up to $80,000,000 (the “Offering”).

    Subject to the terms and conditions of the Sales Agreement, Stifel has agreed to use its commercially reasonable efforts, consistent with its normal sales and trading practices and applicable law and regulations, to sell from time to time the Class A Common Stock so designated by the Company as sales agent in accordance with the Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company cannot provide any assurances that it will issue any Class A Common Stock pursuant to the Sales Agreement. The sales, if any, of the Class A Common Stock under the Sales Agreement will be made by any method permitted that is deemed an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”). The Sales Agreement provides that the commission payable to Stifel for sales of Class A Common Stock with respect to which Stifel acts as sales agent shall be up to 3.0% of the gross proceeds from the sale of such Class A Common Stock sold pursuant to the Sales Agreement. The Sales Agreement contains customary representations and warranties of the parties and indemnification and contribution provisions under which the Company has agreed to indemnify Stifel against certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. The Company will also reimburse Stifel for certain expenses incurred in connection with the Sales Agreement. The Offering will terminate upon the earlier of (i) the sale of all shares of Class A Common Stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Stifel may each terminate the Sales Agreement at any time upon ten days’ prior notice.

    The Company currently intends to use any net proceeds from the Offering to fund further development of new and existing seed traits, Trait Machine maintenance, research and development and for working capital and general corporate purposes.

    The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    The Class A Common Stock will be offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-273062) filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on June 30, 2023, as amended by the pre-effective amendment on Form S-3/A filed on October 25, 2023, and declared effective on October 27, 2023. On January 2, 2024, the Company filed a prospectus supplement with the SEC in connection with the Offering pursuant to the Sales Agreement.

    The legal opinion of Jones Day relating to the legality of the issuance and sale of the Class A Common Stock in the Offering is attached as Exhibit 5.1 to this Current Report on Form 8-K. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state or country in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or country.

     

    Item 8.01

    Other Information.

    In connection with the entry into the Sales Agreement, the Company terminated the Open Market Sales AgreementSM, dated September 21, 2021, by and between the Company (f/k/a Calyxt, Inc.) and Jefferies LLC, as amended by Amendment No. 1 thereto, dated October 3, 2022.


    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    No.

      

    Description

      1.1    Sale Agreement dated January 2, 2024, by and between Cibus, Inc. and Stifel, Nicolaus & Company, Incorporated
      5.1    Opinion of Jones Day
    23.1    Consent of Jones Day (included in Exhibit 5.1)
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        CIBUS, INC.
    Date: January 2, 2024     By:  

    /s/ Rory Riggs

        Name:   Rory Riggs
        Title:   Chief Executive Officer and Chairman
    Get the next $CLXT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLXT

    DatePrice TargetRatingAnalyst
    3/4/2022$6.00 → $4.00Buy
    Canaccord Genuity
    11/2/2021$10.00Buy
    ROTH Capital
    More analyst ratings

    $CLXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Riggs Rory B converted options into 1,500,000 shares and acquired 1,505,967 units of Class B Common Stock, increasing direct ownership by 128% to 3,103,788 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      1/3/24 7:08:08 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      12/14/23 5:10:06 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form 3: New insider Collins James C. Jr. claimed no ownership of stock in the company

      3 - Cibus, Inc. (0001705843) (Issuer)

      9/25/23 4:49:52 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    SEC Filings

    See more
    • Calyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Cibus, Inc. (0001705843) (Filer)

      1/9/24 4:47:04 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Cibus, Inc. (0001705843) (Filer)

      1/2/24 7:15:59 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form 424B5 filed by Calyxt Inc.

      424B5 - Cibus, Inc. (0001705843) (Filer)

      1/2/24 7:07:41 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      12/14/23 5:10:06 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity reiterated coverage on Calyxt with a new price target

      Canaccord Genuity reiterated coverage of Calyxt with a rating of Buy and set a new price target of $4.00 from $6.00 previously

      3/4/22 8:44:27 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • ROTH Capital initiated coverage on Calyxt with a new price target

      ROTH Capital initiated coverage of Calyxt with a rating of Buy and set a new price target of $10.00

      11/2/21 8:38:36 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Canaccord Genuity resumed coverage on Calyxt with a new price target

      Canaccord Genuity resumed coverage of Calyxt with a rating of Buy and set a new price target of $16.00

      2/22/21 7:29:33 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Leadership Updates

    Live Leadership Updates

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calyxt Names IBM's Global Chief Artificial Intelligence Officer, Dr. Seth Dobrin, to Scientific Advisory Board

      ROSEVILLE, Minn., Oct. 12, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biotechnology company, today announced the appointment of Seth Dobrin, Ph.D., to the Company's Scientific Advisory Board (SAB). Dr. Dobrin is the Global Chief Artificial Intelligence (AI) Officer at IBM and brings extensive leadership experience and a track record of transforming companies through data and AI. "We warmly welcome Seth to our Scientific Advisory Board. Seth is a visionary whose deep experience bringing AI-based business solutions to major global corporations will be invaluable as we continue to develop and augment the AI and machine learning (AIML) capabilities of our PlantSprin

      10/12/21 7:00:00 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Appoints Michael A. Carr as Chief Executive Officer

      ROSEVILLE, Minn., July 15, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based biotechnology platform company, today announced the appointment of Michael A. Carr as President and Chief Executive Officer, effective July 27, 2021. Mr. Carr will also serve as a member of Calyxt's Board of Directors. Mr. Carr was most recently the Vice President of M&A, Strategy, and Innovation at Darling Ingredients, Inc., a global developer and producer of sustainable natural ingredients and renewable energy. "Michael's operational, financial, and investment experience, paired with his diverse knowledge across industries including health, nutrients, bioenergy and services will be integral as we adva

      7/15/21 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calyxt Announces Stockholder Approval of Merger With Cibus

      -- Calyxt Announces 1-for-5 Reverse Stock Split of Common Stock -- ROSEVILLE, Minn., May 19, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT) ("Calyxt" or the "Company") today announced the results of the special meeting of its stockholders held on May 18, 2023. At the special meeting, Calyxt's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Class A common stock and Class B common stock to the equity holders of Cibus Global, LLC ("Cibus") as part of the previously announced proposed merger with Cibus. The closing of the merger is anticipated to take place on or around Wednesday, May 31, 2023, subject to the satisfaction of the remainin

      5/19/23 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update

      —Proposed merger with Cibus Global Expected to Close in Q2 2023— —1-for-10 reverse stock split executed— —Current customer projects under development are on track— —Evologic Technologies completed initial phase of project to scale production of Calyxt's Plant Cell Matrix™ and BioFactoryTM technologies— ROSEVILLE, Minn., May 1, 2023 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023. Merger Agreement with Cibus On January 17, 2023, Calyxt announced it had entered into a definitive merger agreement (the Merger Agreement) with Cibus Global, LLC (Cibus), a leader in precis

      5/1/23 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Financials

    Live finance-specific insights

    See more
    • Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      —Successfully produced squalene, an important ingredient for personal care products and vaccine adjuvants— —Continued to progress customer acquisition activities, including evaluating an incremental 37 customer chemistries for development using PlantSpring™ and BioFactory™ technologies— —Signed agreement with Evologic Technologies to further develop and scale production of its Plant Cell Matrix™ technology platform— —Continuing board-level evaluation of a full range of potential strategic alternatives to maximize shareholder value— —Selected for membership to BioMADE, a Department of Defense-sponsored initiative that brings together industrial, academic and non-profit entities to advance US

      11/3/22 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time

      ROSEVILLE, Minn., Oct. 27, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ:CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, November 3, 2022, at 4:30 p.m. ET to discuss results for the third quarter ended September 30, 2022. A press release detailing these results will be issued prior to the call. President and Chief Executive Officer, Michael A. Carr, and Chief Financial Officer, Bill Koschak, will host the conference call. The conference call will be webcast and can be accessed via the investor relations section of the Company's

      10/27/22 7:00:00 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • Calyxt Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      Evaluated nine new customer demand-driven plant-based chemistries in the quarter, bringing cumulative chemistries evaluated for development to 95, of these 31 meet Calyxt's target profile and several are the subject of term sheet discussions Engineering solution for a high-value molecule planned to be delivered in early 2023 to a large global consumer packaged goods company Progressing discussions with multiple potential infrastructure partners who would produce chemistries in various sizes of bioreactors from pilot to commercial scale Evaluating term sheets for technology licensing and for licensing of traits Management to host conference call and webcast today at 4:30 p.m. ET ROSEVILLE, Mi

      8/4/22 4:01:00 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials

    $CLXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Calyxt Inc. (Amendment)

      SC 13G/A - Cibus, Inc. (0001705843) (Subject)

      2/9/24 8:50:20 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13G filed by Calyxt Inc.

      SC 13G - Cibus, Inc. (0001705843) (Subject)

      7/10/23 10:20:11 AM ET
      $CLXT
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13D filed by Calyxt Inc.

      SC 13D - Cibus, Inc. (0001705843) (Subject)

      6/12/23 5:28:58 PM ET
      $CLXT
      Agricultural Chemicals
      Industrials